Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT05976685
Registration number
NCT05976685
Ethics application status
Date submitted
27/07/2023
Date registered
4/08/2023
Date last updated
11/07/2025
Titles & IDs
Public title
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
Query!
Scientific title
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic StrokE Despite Anticoagulation Therapy
Query!
Secondary ID [1]
0
0
2023-02340
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ELAPSE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Ischemic Stroke
0
0
Query!
Atrial Fibrillation
0
0
Query!
Condition category
Condition code
Stroke
0
0
0
0
Query!
Haemorrhagic
Query!
Stroke
0
0
0
0
Query!
Ischaemic
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Surgery - Left atrial appendage Occlusion
Treatment: Drugs - DOAC
Experimental: LAAO and DOAC therapy - Left atrial appendage occlusion and therapy with direct oral anticoagulants
Other: DOAC therapy only - Therapy with direct oral anticoagulants alone
Treatment: Surgery: Left atrial appendage Occlusion
Left atrial appendage Occlusion and therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.
Treatment: Drugs: DOAC
Therapy with direct oral anticoagulants. Choice of DOAC is at the discretion of the treating physician.
Query!
Intervention code [1]
0
0
Treatment: Surgery
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Composite of recurrent ischemic stroke, systemic embolism, or cardiovascular death (whatever comes first).
Query!
Assessment method [1]
0
0
The primary endpoint is the first occurrence of a composite outcome of recurrent ischemic stroke, systemic embolism and cardiovascular death during follow-up. Stoke is defined as - New sudden focal neurological deficit of presumed cerebrovascular aetiology, occurring \> 24 hours after the index ischaemic stroke, that persisted beyond 24 hours and was not due to another identifiable cause 18 (transient ischaemic attack (TIA), defined as a transient episode of neurologic dysfunction caused by focal brain, spinal cord, or retinal ischaemia without cerebral infarction on imaging, is not judged as stroke) and/or by brain imaging (CT or MRI). Systemic embolism is defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion of an extremity or organ in absence of another likely mechanism (e.g. atherosclerosis, instrumentation or trauma). Cardiovascular death is defined as any death that is due to a vascular cause.
Query!
Timepoint [1]
0
0
6 months
Query!
Secondary outcome [1]
0
0
Recurrent ischemic stroke
Query!
Assessment method [1]
0
0
Stoke is defined as - New sudden focal neurological deficit of presumed cerebrovascular aetiology, occurring \> 24 hours after the index ischaemic stroke, that persisted beyond 24 hours and was not due to another identifiable cause 18 (transient ischaemic attack (TIA), defined as a transient episode of neurologic dysfunction caused by focal brain, spinal cord, or retinal ischaemia without cerebral infarction on imaging, is not judged as stroke) and/or by brain imaging (CT or MRI).
Query!
Timepoint [1]
0
0
6 months
Query!
Secondary outcome [2]
0
0
Systemic embolism
Query!
Assessment method [2]
0
0
Systemic embolism is defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion of an extremity or organ in absence of another likely mechanism (e.g. atherosclerosis, instrumentation or trauma).
Query!
Timepoint [2]
0
0
6 months
Query!
Secondary outcome [3]
0
0
Cardiovascular death
Query!
Assessment method [3]
0
0
Cardiovascular death is defined as any death that is due to a vascular cause.
Query!
Timepoint [3]
0
0
6 months
Query!
Secondary outcome [4]
0
0
Symptomatic intracranial hemorrhage
Query!
Assessment method [4]
0
0
A relevant symptomatic intracranial haemorrhage, this includes subdural, epidural, subarachnoidal and intracerebral haemorrhage, is defined as haemorrhage that leads to a clinical worsening and hospitalisation and is assessed by the treating physician to be likely the cause of the new neurological symptom or the death. Intracerebral haemorrhage due to a trauma will not be considered.
Query!
Timepoint [4]
0
0
6 months
Query!
Secondary outcome [5]
0
0
Major extracranial bleeding (ISTH)
Query!
Assessment method [5]
0
0
Definition released by the International Society of Thrombosis and Haemostasis (ISTH): clinically overt bleeding which was fatal or associated with any of the following: (a) a fall in hemoglobin level of 2 g/dL or more or documented transfusion of at least 2 units of packed red blood cells, (b) involvement of a critical anatomical site (intracranial, spinal, ocular, pericardial, articular, intramuscular with compartment syndrome, retroperitoneal).
Query!
Timepoint [5]
0
0
6 months
Query!
Secondary outcome [6]
0
0
Procedure-related death
Query!
Assessment method [6]
0
0
All-cause death within 30 days after randomization or during the index procedure hospitalization
Query!
Timepoint [6]
0
0
6 months
Query!
Secondary outcome [7]
0
0
Serious device- or procedure-related complication
Query!
Assessment method [7]
0
0
7 days post-index procedure for device group subjects
Query!
Timepoint [7]
0
0
6 months
Query!
Secondary outcome [8]
0
0
All-cause hospitalization
Query!
Assessment method [8]
0
0
Any hospital stay of at least 24 hours
Query!
Timepoint [8]
0
0
6 months
Query!
Secondary outcome [9]
0
0
Cause-specific hospitalization
Query!
Assessment method [9]
0
0
Any hospital stay of at least 24 hours or which the primary admitting diagnosis was for heart failure, stroke, bleeding, atrial fibrillation, repeat AF-ablations, periprocedural complication, other cardiovascular causes
Query!
Timepoint [9]
0
0
6 months
Query!
Secondary outcome [10]
0
0
Global health
Query!
Assessment method [10]
0
0
Measured by PROMIS (Patient-reported Outcomes Measurement Information System) Adult Global Health; continuous
Query!
Timepoint [10]
0
0
6 months
Query!
Secondary outcome [11]
0
0
Global safety
Query!
Assessment method [11]
0
0
Measured by FeelSaveScale; continuous
Query!
Timepoint [11]
0
0
6 months
Query!
Secondary outcome [12]
0
0
Functional neurological outcome
Query!
Assessment method [12]
0
0
Modified Rankin Scale; ordinal
Query!
Timepoint [12]
0
0
6 months
Query!
Eligibility
Key inclusion criteria
* Age = 18 years
* Written informed consent
* Permanent, persistent, or paroxysmal spontaneous AF previously known or diagnosed during the index hospitalization.
* Recent (=3 months) symptomatic ischemic stroke.
* Active and ongoing anticoagulation therapy at stroke onset assessed based on medical history (i.e. any therapeutic oral anticoagulation therapy [Vitamin K antagonist/DOAC according to prescription recommendations for AF; inadequate low-dose DOAC therapy allowed for inclusion] not stopped/paused for >48 hours due to any reason, i.e. medical intervention or non-adherence).
* Active or planned long-term therapy with DOAC
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Contraindications to DOAC therapy
* Life expectancy <1 year according to the opinion of the investigator
* Stroke due to: Ipsilateral intra/extracranial high-grade stenosis, Isolated lacunar stroke, Other well-defined stroke aetiologies (i.e., endocarditis, vasculitis, Reversible Cerebral Vasoconstriction Syndrome [RCVS], Posterior Reversible Encephalopathy Syndrome [PRES], cerebral sinus venous thrombosis)
* Previous persistent foramen ovale or atrial septum defect closure.
* Rheumatic heart disease
* Severe heart valve disease that requires treatment (severe aortic stenosis or regurgitation, severe mitral stenosis or regurgitation).
* Contraindications for TEE (relevant esophageal varices, esophageal stricture, history of esophageal cancer).
* Cardiac or non-cardiac surgical procedure within 30 days of randomization
* Enrolled in another investigation of a cardiovascular device or investigating secondary prevention therapy.
* Severely reduced Left Ventricular Ejection Fraction (LVEF) <30%.
* Severe renal impairment as described in the summary of medicinal product characteristics for the chosen DOAC (e.g. rivaroxaban, apixaban and edoxaban creatinine clearance <15 ml/min; dabigatran creatinine clearance <30 ml/min).
* Hypertrophic cardiomyopathy
* Intracardiac tumor
* Ventricular thrombus
* Acute cardiac decompensation
* LAA is obliterated or surgically ligated
* Persistent proximal LAA thrombus despite 4 weeks of anticoagulation (if a proximal thrombus in the LAA is found, anticoagulation with vitamin K antagonist (INR 2.5-3.5) may be started, and if the thrombus disappears, the patient may be eligible for LAAO)
* Pregnancy or breastfeeding (pregnancy test in urine or blood to be performed at screening for women of childbearing potential)
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/05/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/06/2028
Query!
Actual
Query!
Sample size
Target
482
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
Belgium
Query!
State/province [1]
0
0
Brussels
Query!
Country [2]
0
0
Belgium
Query!
State/province [2]
0
0
Charleroi
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Leuven
Query!
Country [4]
0
0
Germany
Query!
State/province [4]
0
0
Schleswig-Holstein
Query!
Country [5]
0
0
Germany
Query!
State/province [5]
0
0
Göttingen
Query!
Country [6]
0
0
Germany
Query!
State/province [6]
0
0
Hamburg
Query!
Country [7]
0
0
Germany
Query!
State/province [7]
0
0
Leipzig
Query!
Country [8]
0
0
Germany
Query!
State/province [8]
0
0
Mannheim
Query!
Country [9]
0
0
New Zealand
Query!
State/province [9]
0
0
Christchurch
Query!
Country [10]
0
0
Switzerland
Query!
State/province [10]
0
0
Ticino
Query!
Country [11]
0
0
Switzerland
Query!
State/province [11]
0
0
Vaude
Query!
Country [12]
0
0
Switzerland
Query!
State/province [12]
0
0
Basel
Query!
Country [13]
0
0
Switzerland
Query!
State/province [13]
0
0
Bern
Query!
Country [14]
0
0
Switzerland
Query!
State/province [14]
0
0
Geneva
Query!
Country [15]
0
0
Switzerland
Query!
State/province [15]
0
0
Lucerne
Query!
Country [16]
0
0
Switzerland
Query!
State/province [16]
0
0
Saint Gallen
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Insel Gruppe AG, University Hospital Bern
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and cardioembolic stroke due to AF is its major complication. Direct oral anticoagulants (DOAC) reduce the risk of cardioembolism in patients with AF. Despite DOAC therapy, there is a significant residual stroke risk of 1-2%/year. Recent data from the Swiss Stroke Registry found 38% of patients with AF and ischemic stroke were on prior anticoagulant therapy (approximately 400 patients per year in Switzerland). The investigators found in a prior observational study, that patients with AF who have ischemic stroke despite anticoagulation are at increased risk of having another ischemic stroke (HR 1.6; 95% confidence interval, CI 1.1-2.1). Combining observational data from 11 international stroke centres, the investigators found that the majority of ischemic strokes despite anticoagulation in patients with AF is "breakthrough" cardioembolism (76% of patients) and only a minority of 24% is related to other causes unrelated to AF. Optimal secondary prevention strategy is unknown. The investigators have conducted two independent observational studies including together \>4000 patients but did not identify any strategy (e.g. switch to different DOAC, additional antiplatelet therapy) that seems superior. A recent randomized controlled trial on surgical occlusion of the left atrial appendage (LAAO) found that LAAO may provide additional protection from ischaemic stroke in addition to oral anticoagulation. Triggered by this finding, the investigators performed a matched retrospective observational study and found that patients with AF and stroke despite anticoagulation who received a combined mechanical-pharmacological therapy (DOAC therapy + LAAO) had lower rates of adverse outcomes compared to those with DOAC therapy alone. Therefore, the investigators hypothesize that in patients with AF and ischemic stroke despite anticoagulant therapy, LAAO in addition to anticoagulation with a DOAC is superior to DOAC therapy alone. The investigators propose an international, multi-center randomized controlled two-arm trial to assess the effect of LAAO in patients with AF suffering from strokes despite anticoagulation therapy and without competing stroke etiology. The investigators will use the PROBE design with blinded endpoint assessment. The investigators will enrol patients with non-valvular AF and a recent ischemic stroke despite anticoagulation therapy at stroke onset. Patients will be randomized 1:1 to receive LAAO + DOAC therapy (experimental arm) or DOAC therapy alone (standard treatment arm). The primary endpoint is the first occurrence of a composite outcome of recurrent ischemic stroke, systemic embolism and cardiovascular death during follow-up. Secondary outcomes include individual components of the primary composite outcome, safety outcomes (i.e. symptomatic intracranial haemorrhage, major extracranial bleeding, serious device- or procedure-related complication), functional outcome (modified Rankin Scale) and patient-oriented outcomes. The minimum follow-up is 6 months and all patients will receive follow-ups every 6 months until end of study, the maximal follow-up will be 48 months. Based on prior observational data from the investigators' group and others (5 observational studies, \>5000 patients), the investigators estimate the proportion of patients with the primary outcome in the standard treatment arm to be 18% in the first year and 9% in the second year (=cumulative 27% after 2 years). A relative risk reduction of 40% at 2 years would be clinically relevant. Based on these assumptions and a log-rank test, the investigators would need 98 events for a power of 80% at an alpha-level of 5%. Assuming a recruitment rate of 52, 118, 156 and 156 patients in years 1 to 4, an additional 6 months of follow-up (mean follow-up time of 2.1 years) and a uniform drop-out rate of 7.5% per year, 482 patients would need to be enrolled. How to treat patients with an ischemic stroke despite anticoagulation is a major yet unresolved clinical dilemma. This trial has the potential to answer the question whether LAAO plus DOAC therapy is superior to current standard of care for patients with AF who have ischemic stroke despite anticoagulation.
Query!
Trial website
https://clinicaltrials.gov/study/NCT05976685
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Lorenz Räber, Prof., MD
Query!
Address
0
0
Cardiovascular Center, Inselspital Bern
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Lorenz Räber, Prof., MD, PhD
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+41316320929
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT05976685
Download to PDF